Korean J Psychopharmacol.
2005 Jul;16(4):324-328.
Selection of an Antidepressant Based on the Genotypes of Cytochrome P450 Enzymes Genes in a Patient with Major Depressive Disorder
- Affiliations
-
- 1Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kshong@smc.samsung.co.kr
- 2Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
- We present a case of 34-year-old female patient with major depressive disorder who had decreased metabolic activity of CYP2D6. Low dosage regimen of mirtazapine & paroxetine led to unexpectedly severe adverse effects and noncompliance in this case with genotype CYP2D6 *1/*5. Antidepressant change to imipramine with consideration of the genotyping resulted with tolerable adverse effects and remission of depression. This case suggests the clinical usefulness of pharmacogenetic testing in individualized antidepressant treatments.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Inhibition of Cytochrome P450 Enzymes by Drugs—Molecular Basis and Practical Applications
- Streptomyces Cytochrome P450 Enzymes and Their Roles in the Biosynthesis of Macrolide Therapeutic Agents
- Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
- Cytochrome P450 and Cancer
- A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
